1176 related articles for article (PubMed ID: 31258138)
1. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
7. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
10. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
12. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.
Rivière B; Jaussent A; Macioce V; Faure S; Builles N; Lefebvre P; Géraud P; Picot MC; Rebuffat S; Renard E; Paradis V; Servais MD; de Preville N; Nocca D; Lajoix AD; Pageaux GP; Galtier F;
Diabetes Metab; 2022 Jul; 48(4):101345. PubMed ID: 35339664
[TBL] [Abstract][Full Text] [Related]
13. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Akyuz U; Yesil A; Yilmaz Y
Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
[TBL] [Abstract][Full Text] [Related]
14. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
15. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
17. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
20. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
